E0 ConsensusPreliminaryPEM unclearReview-NarrativePeer-reviewedReviewed
Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying Biological Mechanisms: Implications for Future Therapeutic Strategies.
Mantle, David, Domingo, Joan Carles, Golomb, Beatrice Alexandra et al. · International journal of molecular sciences · 2025 · DOI
Quick Summary
This review examines four conditions—Gulf War Illness, fibromyalgia, ME/CFS, and long COVID—that share similar symptoms like fatigue, pain, and brain fog. Researchers found that these disorders may share common biological problems, particularly with how cells produce energy (mitochondria), manage stress, and control inflammation. The authors suggest that a supplement called CoQ10 might help because it supports cellular energy production and reduces harmful inflammation.
Why It Matters
This review validates that ME/CFS shares fundamental biological abnormalities with other recognized conditions, potentially strengthening research funding and clinical recognition. Identifying a common mechanistic framework suggests that therapies addressing mitochondrial function and oxidative stress could benefit multiple patient populations, offering hope for a more unified therapeutic approach.
Observed Findings
- Four distinct disorders (GWI, FM, ME/CFS, long COVID) share overlapping symptom profiles and symptom burden.
- Mitochondrial dysfunction, oxidative stress, immune dysregulation, and neuroendocrine disruption appear as common biological features across all four conditions.
- Inflammation and disrupted gut-microbiome signaling are reported in each disorder.
- Telomere shortening and apoptosis/ferroptosis have been identified in multiple conditions.
- CoQ10 has theoretical and some empirical support in each condition due to its antioxidant, anti-inflammatory, and mitochondrial-supporting properties.
Inferred Conclusions
- These four conditions comprise a related group of 'low-energy associated disorders' with convergent biological pathways despite distinct etiologies.
- CoQ10 supplementation represents a rational therapeutic strategy warranting further clinical investigation in ME/CFS and related conditions.
- Therapies targeting shared mechanisms (mitochondrial function, oxidative stress, immune dysregulation) may benefit multiple patient populations.
Remaining Questions
- What are the optimal doses, formulations, and treatment durations for CoQ10 in ME/CFS patients specifically?
- Which pathological mechanisms are primary drivers versus secondary consequences in ME/CFS?
What This Study Does Not Prove
This review does not prove that CoQ10 supplementation is clinically effective in ME/CFS patients—it identifies biological rationale and reports preliminary findings, but robust clinical trials are needed. The review also does not establish that mitochondrial dysfunction is the primary cause of these disorders, only that it appears to be one of several overlapping pathological features.
Tags
Symptom:Cognitive DysfunctionPainFatiguePost-Exertional Malaise
Biomarker:CytokinesMetabolomicsGene ExpressionBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:Weak Case DefinitionExploratory OnlyMixed Cohort
Metadata
- DOI
- 10.3390/ijms26189044
- PMID
- 41009608
- Review status
- Editor reviewed
- Evidence level
- Established evidence from major reviews, guidelines, or evidence maps
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.